Mirae Asset Global Investments Co. Ltd. Reduces Stake in uniQure (NASDAQ:QURE)

Mirae Asset Global Investments Co. Ltd. lowered its position in uniQure (NASDAQ:QURE) by 57.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 90,354 shares of the biotechnology company’s stock after selling 124,332 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in uniQure were worth $612,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of the company. Raymond James & Associates boosted its position in uniQure by 6.4% in the fourth quarter. Raymond James & Associates now owns 52,224 shares of the biotechnology company’s stock valued at $354,000 after buying an additional 3,145 shares during the last quarter. Harbor Capital Advisors Inc. lifted its holdings in uniQure by 17.8% in the third quarter. Harbor Capital Advisors Inc. now owns 25,494 shares of the biotechnology company’s stock valued at $171,000 after acquiring an additional 3,850 shares during the period. BluePath Capital Management LLC acquired a new position in uniQure in the third quarter valued at approximately $27,000. China Universal Asset Management Co. Ltd. lifted its holdings in uniQure by 222.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,258 shares of the biotechnology company’s stock valued at $42,000 after acquiring an additional 4,315 shares during the period. Finally, Headlands Technologies LLC acquired a new position in uniQure in the third quarter valued at approximately $31,000. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Stock Down 0.4 %

NASDAQ QURE opened at $4.54 on Friday. The business has a fifty day moving average price of $5.30 and a 200 day moving average price of $6.00. uniQure has a one year low of $4.35 and a one year high of $22.48. The company has a debt-to-equity ratio of 0.49, a quick ratio of 8.68 and a current ratio of 8.85. The company has a market cap of $217.19 million, a P/E ratio of -0.70 and a beta of 0.95.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Wednesday, February 28th. The biotechnology company reported ($1.53) EPS for the quarter, beating the consensus estimate of ($1.54) by $0.01. uniQure had a negative return on equity of 99.31% and a negative net margin of 1,947.09%. The firm had revenue of $6.69 million during the quarter, compared to the consensus estimate of $3.20 million. Research analysts anticipate that uniQure will post -4.49 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. StockNews.com raised uniQure to a “sell” rating in a report on Friday, March 1st. Royal Bank of Canada reissued an “outperform” rating and issued a $28.00 price target on shares of uniQure in a report on Tuesday, January 16th. Mizuho reduced their target price on uniQure from $10.00 to $7.00 and set a “neutral” rating for the company in a research note on Monday, March 4th. HC Wainwright reduced their target price on uniQure from $30.00 to $25.00 and set a “buy” rating for the company in a research note on Friday, March 1st. Finally, The Goldman Sachs Group downgraded uniQure from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $63.00 to $8.00 in a research note on Thursday, February 29th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, uniQure presently has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

Insider Activity at uniQure

In related news, COO Pierre Caloz sold 9,455 shares of the stock in a transaction on Monday, February 26th. The stock was sold at an average price of $6.47, for a total value of $61,173.85. Following the completion of the transaction, the chief operating officer now directly owns 85,643 shares of the company’s stock, valued at approximately $554,110.21. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other uniQure news, COO Pierre Caloz sold 9,455 shares of the company’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $6.47, for a total value of $61,173.85. Following the completion of the sale, the chief operating officer now directly owns 85,643 shares in the company, valued at approximately $554,110.21. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Matthew C. Kapusta sold 27,904 shares of the company’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $6.35, for a total value of $177,190.40. Following the completion of the sale, the chief executive officer now owns 440,839 shares of the company’s stock, valued at $2,799,327.65. The disclosure for this sale can be found here. In the last ninety days, insiders sold 53,265 shares of company stock valued at $339,845. 4.05% of the stock is owned by insiders.

uniQure Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.